Folate Deficiency Correlates with Severity of Primary Biliary Cholangitis via Modulating Key Regulatory Genes

Why It Matters

Identifying folate as a modifiable risk factor offers a novel diagnostic tool and a therapeutic target for a disease where up to 40% of patients fail standard ursodeoxycholic acid therapy.

Key Takeaways

• Serum folate inversely linked to ALT, AST, GGT, IgG, and LSM.
• Combined folate, DBIL, and LSM panel yields AUC 0.974 for advanced PBC.
• ARID3B and MXD1 proteins rise as folate levels drop.
• Transcriptome shows 2,363–5,648 DEGs enriched in immune and metabolic pathways.
• Folate deficiency may create a bidirectional cycle worsening PBC progression.

Pulse Analysis

Primary biliary cholangitis remains a leading cause of end‑stage liver disease, especially among middle‑aged women. While ursodeoxycholic acid benefits many, a sizable minority experience disease progression, prompting a search for additional biomarkers. Folate, a B‑vitamin essential for DNA synthesis, methylation and antioxidant defenses, has emerged as a candidate because the liver stores the majority of the body’s folate pool. Recent epidemiologic work links low folate to several autoimmune conditions, suggesting that folate status could influence immune dysregulation in PBC.

The June 2026 Frontiers in Nutrition study provides the first comprehensive clinical‑transcriptomic assessment of folate in PBC. Researchers measured serum folate in 90 patients and matched controls, finding a stepwise decline from early to late disease stages. Correlation analyses tied lower folate to higher ALT, AST, GGT, IgG and liver stiffness, while multivariate modeling confirmed folate as an independent protective factor. A diagnostic algorithm that combined folate with direct bilirubin and transient elastography outperformed each marker alone, achieving an AUC of 0.974. RNA‑seq uncovered thousands of differentially expressed genes, with pathway enrichment highlighting immune activation and metabolic disruption. Protein validation singled out ARID3B, MXD1, AHRR and P2RY14 as folate‑responsive effectors, implicating epigenetic regulation, Th17 immunity and purinergic signaling in disease pathogenesis.

Clinically, these findings suggest that routine folate assessment could refine risk stratification and guide early intervention. Moreover, the bidirectional relationship—where PBC impairs folate absorption and folate deficiency fuels hepatic injury—raises the prospect of supplementation as an adjunct therapy. Prospective trials are needed to determine whether correcting folate deficiency can halt or reverse fibrosis, improve response to ursodeoxycholic acid, or reduce the need for liver transplantation. Until then, clinicians should consider monitoring folate levels, especially in patients with advanced disease or suboptimal treatment response.